Pages that link to "Q30855755"
Jump to navigation
Jump to search
The following pages link to Genetic polymorphisms of RANTES, IL1-A, MCP-1 and TNF-A genes in patients with prostate cancer (Q30855755):
Displaying 31 items.
- Chemokine signaling in cancer: Implications on the tumor microenvironment and therapeutic targeting (Q34010429) (← links)
- IL-1α -889 C/T polymorphism and cancer susceptibility: a meta-analysis (Q34523165) (← links)
- Metabolic imbalance and prostate cancer progression. (Q34794028) (← links)
- Association between MCP-1 -2518A/G polymorphism and cancer risk: evidence from 19 case-control studies (Q35075456) (← links)
- Association between tumor necrosis factor-alpha gene polymorphisms and prostate cancer risk: a meta-analysis (Q35130586) (← links)
- Polymorphisms in inflammatory genes, plasma antioxidants, and prostate cancer risk (Q35516448) (← links)
- Associations of immunity-related single nucleotide polymorphisms with overall survival among prostate cancer patients (Q36046753) (← links)
- Chemokine polymorphisms and lymphoma: a pooled analysis (Q36237839) (← links)
- Association between hepatocellular carcinoma and tumor necrosis factor alpha polymorphisms in South Korea (Q36360813) (← links)
- Chemokine Ligand 5 (CCL5) and chemokine receptor (CCR5) genetic variants and prostate cancer risk among men of African Descent: a case-control study (Q36480538) (← links)
- Inflammatory genetic markers of prostate cancer risk (Q37328413) (← links)
- -2518 A/G MCP-1 but not -403 G/A RANTES gene polymorphism is associated with enhanced risk of basal cell carcinoma. (Q37416312) (← links)
- Chemokines as targets for therapy (Q37849900) (← links)
- Down-modulation of TNFSF15 in ovarian cancer by VEGF and MCP-1 is a pre-requisite for tumor neovascularization (Q39419250) (← links)
- Inherited variants in the chemokine CCL2 gene and prostate cancer aggressiveness in a Caucasian cohort (Q42700287) (← links)
- RANTES polymorphisms and the risk of graft-versus-host disease in human leukocyte antigen-matched sibling allogeneic hematopoietic stem cell transplantation (Q43809862) (← links)
- Association study of chemokine (C-C motif) ligand 5 gene polymorphism and papillary thyroid cancer (Q47749007) (← links)
- The possible role of the tumour necrosis factor polymorphisms and human leucocyte antigens in the development of prostate cancer. (Q53117530) (← links)
- Significance of Tumor necrosis factor α-308 (G/A) gene polymorphism in the development of prostate cancer. (Q53263340) (← links)
- Association of IL‐1 polymorphisms and IL‐1 serum levels with susceptibility to nasopharyngeal carcinoma (Q54397543) (← links)
- Study of TLR3, TLR4, and TLR9 in prostate carcinomas and their association with biochemical recurrence (Q54404821) (← links)
- Opposing effects of pro- and anti-inflammatory cytokine gene polymorphisms on the risk for breast cancer in western Indian women: a pilot study. (Q54687752) (← links)
- Genetic variants in CCL5 and CCR5 genes and serum VEGF-A levels predict efficacy of bevacizumab in metastatic colorectal cancer patients (Q58565029) (← links)
- Genetic variants of chemokine CCL2 and chemokine receptor CCR2 genes and risk of prostate cancer (Q62632237) (← links)
- CCR2-64I gene polymorphism increase susceptibility to oral cancer (Q84098111) (← links)
- CCL2 -2518 A/G single nucleotide polymorphism as a risk factor for breast cancer (Q84444139) (← links)
- Tumour Necrosis Factor-α Polymorphisms and Hepatocellular Carcinoma: A Meta-analysis (Q84988636) (← links)
- A MCP-1 promoter polymorphism at G-2518A is associated with spontaneous preterm birth (Q85334828) (← links)
- CCL5-403, CCR5-59029, and Delta32 polymorphisms and cancer risk: a meta-analysis based on 20,625 subjects (Q87573854) (← links)
- Role of CCL5 and CCR5 gene polymorphisms in epidermal growth factor receptor signalling blockade in metastatic colorectal cancer: analysis of the FIRE-3 trial (Q90559801) (← links)
- No association between three polymorphisms (rs1800629, rs361525 and rs1799724) in the tumor necrosis factor-α gene and susceptibility to prostate cancer: a comprehensive meta-analysis (Q91704953) (← links)